
A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is
2 amended by amending subsection (b) to read as follows:

3 "(b) Any of the following opiates, including their
4 isomers, esters, ethers, salts, and salts of isomers, esters,
5 and ethers, unless specifically excepted, whenever the existence
6 of these isomers, esters, ethers, and salts is possible within
7 the specific chemical designation:

- 8 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-
9 phenethyl)-4-piperidinyl]-N-phenylacetamide);
- 10 (2) Acetylmethadol;
- 11 (3) Allylprodine;
- 12 (4) Alphacetylmethadol (except levo-alphacetylmethadol,
13 levomethadyl acetate, or LAAM);
- 14 (5) Alphameprodine;
- 15 (6) Alphamethadol;
- 16 (7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
17 phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-
18 2-phenylethyl)-4-(N-propanilido) piperidine);

H.B. NO. 1032

- 1 (8) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
- 2 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 3 (9) Benzethidine;
- 4 (10) Betacetylmethadol;
- 5 (11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
- 6 piperidinyl]-N-phenylpropanamide);
- 7 (12) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-
- 8 phenethyl)-3-methyl-4-piperidinyl]-N-
- 9 phenylpropanamide);
- 10 (13) Betameprodine;
- 11 (14) Betamethadol;
- 12 (15) Betaprodine;
- 13 (16) Clonitazene;
- 14 (17) Dextromoramide;
- 15 (18) Diampromide;
- 16 (19) Diethylthiambutene;
- 17 (20) Difenoazin;
- 18 (21) Dimenoxadol;
- 19 (22) Dimepheptanol;
- 20 (23) Dimethylthiambutene;
- 21 (24) Dioxaphetyl butyrate;
- 22 (25) Dipipanone;

H.B. NO. 1032

- 1 (26) Ethylmethylthiambutene;
- 2 (27) Etonitazene;
- 3 (28) Etoxeridine;
- 4 (29) Furethidine;
- 5 (30) Hydroxypethidine;
- 6 (31) Ketobemidone;
- 7 (32) Levomoramide;
- 8 (33) Levophenacymorphan;
- 9 (34) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
- 10 piperidyl]-N-phenylpropanamide);
- 11 (35) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-
- 12 4-piperidinyl]-N-phenylpropanamide);
- 13 (36) Morpheridine;
- 14 (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 15 (38) Noracymethadol;
- 16 (39) Norlevorphanol;
- 17 (40) Normethadone;
- 18 (41) Norpipanone;
- 19 (42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
- 20 phenethyl)-4-piperidinyl] propanamide;
- 21 (43) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;
- 22 (44) Phenadoxone;

H.B. NO. 1032

- 1 (45) Phenampromide;
- 2 (46) Phenomorphan;
- 3 (47) Phenoperidine;
- 4 (48) Piritramide;
- 5 (49) Proheptazine;
- 6 (50) Properidine;
- 7 (51) Propiram;
- 8 (52) Racemoramide;
- 9 (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl) ethyl-4-
- 10 piperidiny]l]-propanamide);
- 11 (54) Tilidine;
- 12 (55) Trimeperidine;
- 13 (56) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
- 14 (benzylfentanyl), its optical isomers, salts, and
- 15 salts of isomers;
- 16 (57) N-[1-(2-thienyl)methyl-4-piperidyl]-N-
- 17 phenylpropanamide (thenylfentanyl), its optical
- 18 isomers, salts, and salts of isomers;
- 19 (58) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,
- 20 (acetyl fentanyl), its optical, positional, and
- 21 geometric isomers, salts, and salts of isomers;

H.B. NO. 1032

- 1 (59) AH-7921 (3,4-dichloro-*N*-[(1- dimethylamino)
2 cyclohexylmethyl]benzamide), its isomers, esters,
3 ethers, salts, and salts of isomers, esters, and
4 ethers;
- 5 (60) *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutyramide, its
6 isomers, esters, ethers, salts, and salts of isomers,
7 esters, and ethers (Other names: Butyryl fentanyl);
- 8 (61) *N*-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-
9 yl]-*N*-phenylpropionamide, its isomers, esters, ethers,
10 salts and salts of isomers, esters, and ethers (Other
11 names: beta-hydroxythiofentanyl);
- 12 (62) *N*-(1-phenthylpiperidin-4-yl)-*N*-phenylfuran-2-
13 carboxamide, its isomers, esters, ethers, salts, and
14 salts of isomer, esters, and ethers (other names:
15 Furanyl fentanyl);
- 16 (63) 3,4-dicholoro-*N*-[2-(dimethylamino)cyclohexyl]-*N*-
17 methylbenzamide, its isomers, esters, ethers, salts
18 and salts of isomers, esters, and ethers (Other names:
19 U-47700);
- 20 (64) 4-fluoroisobutyryl fentanyl or para-fluoroisobutyryl
21 fentanyl [*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-
22 4-yl)isobutyramide];

H.B. NO. 1032

- 1 (65) Acryl fentanyl or acryloylfentanyl [N-(1-
2 phenethylpiperidin-4-yl)-N-phenylacrylamide]; [~~and~~]
- 3 (66) Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-
4 phenethylpiperidin-4-yl)acetamide] [~~-~~];
- 5 (67) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
6 phenylcyclopropanecarboxamide;
- 7 (68) Methoxyacetyl fentanyl (2-methoxy-N-(1-
8 phenethylpiperidin-4-yl)-N-phenylacetamide);
- 9 (69) ortho-Fluorofentanyl (N-(2-fluorophenyl)-N-(1-
10 phenethylpiperidin-4-yl)propionamide); other name: 2-
11 fluorofentanyl); and
- 12 (70) para-Fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
13 phenethylpiperidin-4-yl)butyramide)."

14 SECTION 2. Section 329-14, Hawaii Revised Statutes, is
15 amended by amending subsection (e) to read as follows:

16 "(e) Depressants. Unless specifically excepted, the
17 schedule shall include any material, compound, mixture, or
18 preparation which contains any quantity of the substance:

- 19 (1) Mecloqualone; [~~or~~]
- 20 (2) Methaqualone [~~-~~];

H.B. NO. 1032

1 (3) Etizolam (including its optical, positional, and
2 geometric isomers, salts, and salts of isomers, where
3 possible); or

4 (4) Flualprazolam (including its optical, positional, and
5 geometric isomers, salts, and salts of isomers, where
6 possible)."

7 SECTION 3. Section 329-14, Hawaii Revised Statutes, is
8 amended by amending subsection (g) to read as follows:

9 "(g) Any of the following cannabinoids, their salts,
10 isomers, and salts of isomers, unless specifically excepted,
11 whenever the existence of these salts, isomers, and salts of
12 isomers is possible within the specific chemical designation:

13 (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
14 naturally contained in a plant of the genus Cannabis
15 (cannabis plant), as well as synthetic equivalents of
16 the substances contained in the plant, or in the
17 resinous extractives of Cannabis, sp. or synthetic
18 substances, derivatives, and their isomers with
19 similar chemical structure and pharmacological
20 activity to those substances contained in the plant,
21 such as the following: Delta 1 cis or trans
22 tetrahydrocannabinol, and their optical isomers; Delta

H.B. NO. 1032

1 6 cis or trans tetrahydrocannabinol, and their optical
2 isomers; and Delta 3,4 cis or trans-
3 tetrahydrocannabinol, and its optical isomers (since
4 nomenclature of these substances is not
5 internationally standardized, compounds of these
6 structures, regardless of numerical designation of
7 atomic positions, are covered);

8 (2) Naphthoylindoles; meaning any compound containing a 3-
9 (1-naphthoyl)indole structure with substitution at the
10 nitrogen atom of the indole ring by a alkyl,
11 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
12 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
13 morpholinyl)ethyl group, whether or not further
14 substituted in the indole ring to any extent and
15 whether or not substituted in the naphthyl ring to any
16 extent;

17 (3) Naphthylmethylinindoles; meaning any compound containing
18 a 1H-indol-3-yl-(1-naphthyl) methane structure with
19 substitution at the nitrogen atom of the indole ring
20 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
21 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
22 2-(4-morpholinyl) ethyl group whether or not further

H.B. NO. 1032

1 substituted in the indole ring to any extent and
2 whether or not substituted in the naphthyl ring to any
3 extent;

4 (4) Naphthoylpyrroles; meaning any compound containing a
5 3-(1-naphthoyl)pyrrole structure with substitution at
6 the nitrogen atom of the pyrrole ring by a alkyl,
7 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
8 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)
9 ethyl group whether or not further substituted in the
10 pyrrole ring to any extent, whether or not substituted
11 in the naphthyl ring to any extent;

12 (5) Naphthylmethylindenes; meaning any compound containing
13 a naphthylideneindene structure with substitution at
14 the 3-position of the indene ring by a alkyl,
15 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
16 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
17 ethyl group whether or not further substituted in the
18 indene ring to any extent, whether or not substituted
19 in the naphthyl ring to any extent;

20 (6) Phenylacetylindoles; meaning any compound containing a
21 3-phenylacetylindole structure with substitution at
22 the nitrogen atom of the indole ring by a alkyl,

H.B. NO. 1032

1 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
2 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
3 ethyl group whether or not further substituted in the
4 indole ring to any extent, whether or not substituted
5 in the phenyl ring to any extent;

6 (7) Cyclohexylphenols; meaning any compound containing a
7 2-(3-hydroxycyclohexyl) phenol structure with
8 substitution at the 5-position of the phenolic ring by
9 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
10 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
11 2-(4-morpholinyl) ethyl group whether or not
12 substituted in the cyclohexyl ring to any extent;

13 (8) Benzoylindoles; meaning any compound containing a 3-
14 (benzoyl) indole structure with substitution at the
15 nitrogen atom of the indole ring by a alkyl,
16 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
17 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-
18 morpholinyl) ethyl group whether or not further
19 substituted in the indole ring to any extent and
20 whether or not substituted in the phenyl ring to any
21 extent;

H.B. NO. 1032

- 1 (9) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
2 pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
3 naphthalenylmethanone (another trade name is WIN
4 55,212-2);
- 5 (10) (6a,10a)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
6 methyloctan-2-yl)-6a,7,10,10a-
7 tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
8 HU-210/HU-211);
- 9 (11) Tetramethylcyclopropanoylindoles; meaning any compound
10 containing a 3-tetramethylcyclopropanoylindole
11 structure with substitution at the nitrogen atom of
12 the indole ring by an alkyl, haloalkyl, cyanoalkyl,
13 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
14 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
15 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
16 morpholinyl)methyl, or tetrahydropyranylmethyl group,
17 whether or not further substituted in the indole ring
18 to any extent and whether or not substituted in the
19 tetramethylcyclopropyl ring to any extent;
- 20 (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
21 its optical, positional, and geometric isomers, salts,
22 and salts of isomers (Other names: APINACA, AKB48);

H .B. NO. 1032

- 1 (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
2 optical, positional, and geometric isomers, salts, and
3 salts of isomers (Other names: PB-22; QUPIC);
- 4 (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
5 carboxylate, its optical, positional, and geometric
6 isomers, salts, and salts of isomers (Other names: 5-
7 fluoro-PB-22; 5F-PB-22);
- 8 (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
9 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
10 positional, and geometric isomers, salts, and salts of
11 isomers (Other names: AB-FUBINACA);
- 12 (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
13 indazole-3-carboxamide, its optical, positional, and
14 geometric isomers, salts, and salts of isomers (Other
15 names: ADB-PINACA);
- 16 (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
17 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its
18 optical, positional, and geometric isomers, salts, and
19 salts of isomers (Other names: AB-CHMINACA);
- 20 (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
21 indazole-3-carboxamide, and geometric isomers, salts,
22 and salts of isomers (Other names: AB-PINACA);

H.B. NO. 1032

- 1 (19) [1-(5-fluoropentyl)-1H-indazol-3-yl] (naphthalen-1-
2 yl)methanone, and geometric isomers, salts, and salts
3 of isomers (Other names: THJ-2201);
- 4 (20) Methyl (1-(4-fluorobenzyl)-1 H-indazole-3-carbonyl)-L-
5 valinate, and geometric isomers, salts, and salts of
6 isomers (Other names: FUB-AMB[+] [⚡], Methyl 2-(1-(4-
7 fluorobenzyl)-1H-indazole-3-carboxamido)-3-
8 methylbutanoate, MMB-FUBINACA, AMB-FUBINACA);
- 9 (21) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
10 carboxamido)-3-methylbutanoate, and geometric isomers,
11 salts, and salts of isomers (Other names: 5-fluoro-
12 AMB, 5-fluoro-AMP);
- 13 (22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
14 indazole-3-carboxamide, and geometric isomers, salts,
15 and salts of isomers (Other names: AKB48 N-(5-
16 fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
17 analog, 5F-APINACA);
- 18 (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
19 geometric isomers, salts, and salts of isomers (Other
20 names: STS-135, 5F-APICA; 5-fluoro-APICA);

H.B. NO. 1032

- 1 (24) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
2 carboxylate, and geometric isomers, salts, and salts
3 of isomers (Other names: NM2201);
- 4 (25) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
5 (cyclohexylmethyl)-1H-indazole-3-carboxamide, and
6 geometric isomers, salts, and salts of isomers (Other
7 names: MAB-CHMINACA and ADB-CHMINACA);
- 8 (26) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-
9 carboxamido]-3,3-dimethylbutanoate (Other names: 5F-
10 ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,
11 positional, and geometric isomers, salts, and salts of
12 isomers; and
- 13 (27) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
14 carboxamide (CUMYL-4CN-BINACA), its optical,
15 positional, and geometric isomers, salts, and salts of
16 isomers; also known as SGT-78, 4-CN-CUMYL-BINACA;
17 CUMYL-CB-PINACA; CUMYL-CYBINACA; 4-cyano CUMYL-
18 BUTINACA."

19 SECTION 4. Section 329-16, Hawaii Revised Statutes, is
20 amended by amending subsection (f) to read as follows:

H.B. NO. 1032

1 "(f) Immediate precursor. Unless listed in another
2 schedule, any material, compound, mixture, or preparation which
3 contains any quantity of the following substances:

4 (1) Immediate precursor to amphetamine and
5 methamphetamine:

6 (A) Phenylacetone, phenyl-2-propanone (P2P), benzyl
7 methyl ketone, methyl benzyl ketone;

8 (2) Immediate precursors to phencyclidine (PCP):

9 (A) 1-phenylcyclohexylamine; [~~and~~] or

10 (B) 1-piperidinocyclohexanecarbonitrile (PCC); or

11 (3) Immediate precursor to Fentanyl:

12 (A) 4-anilino-N-phenethyl-4-piperidine (ANPP) [~~-~~]; or

13 (B) N-phenyl-N-(piperidin-4-yl)propionamide

14 (norfentanyl)."

15 SECTION 5. Section 329-20, Hawaii Revised Statutes, is
16 amended by amending subsection (b) to read as follows:

17 "(b) Depressants. Any material, compound, mixture, or
18 preparation which contains any quantity of the following
19 substances, including its salts, isomers, esters, ethers, and
20 salts of isomers, whenever the existence of these isomers,
21 esters, ethers, and salts is possible within the specific
22 chemical designation, that has a degree of danger or probable

H.B. NO. 1032

1 danger associated with a depressant effect on the central
2 nervous system:

- 3 (1) Alprazolam;
- 4 (2) Barbital;
- 5 (3) Bromazepam;
- 6 (4) Butorphanol;
- 7 (5) Camazepam;
- 8 (6) Carisoprodol;
- 9 (7) Chloral betaine;
- 10 (8) Chloral hydrate;
- 11 (9) Chlordiazepoxide;
- 12 (10) Clobazam;
- 13 (11) Clonazepam;
- 14 (12) Clorazepate;
- 15 (13) Clotiazepam;
- 16 (14) Cloxazolam;
- 17 (15) Delorazepam;
- 18 (16) Dichloralphenazone (Midrin);
- 19 (17) Diazepam;
- 20 (18) Estazolam;
- 21 (19) Ethchlorvynol;
- 22 (20) Ethinamate;

H.B. NO. 1032

- 1 (21) Ethyl loflazepate;
- 2 (22) Fludiazepam;
- 3 (23) Flunitrazepam;
- 4 (24) Flurazepam;
- 5 (25) Fospropofol (Lusedra);
- 6 (26) Halazepam;
- 7 (27) Haloxazolam;
- 8 (28) Ketazolam;
- 9 (29) Loprazolam;
- 10 (30) Lorazepam;
- 11 (31) Lormetazepam;
- 12 (32) Mebutamate;
- 13 (33) Medazepam;
- 14 (34) Meprobamate;
- 15 (35) Methohexital;
- 16 (36) Methylphenobarbital (mephobarbital);
- 17 (37) Midazolam;
- 18 (38) Nimetazepam;
- 19 (39) Nitrazepam;
- 20 (40) Nordiazepam;
- 21 (41) Oxazepam;
- 22 (42) Oxazolam;

H.B. NO. 1032

- 1 (43) Paraldehyde;
- 2 (44) Petrichloral;
- 3 (45) Phenobarbital;
- 4 (46) Pinazepam;
- 5 (47) Prazepam;
- 6 (48) Quazepam;
- 7 (49) Suvorexant;
- 8 (50) Temazepam;
- 9 (51) Tetrazepam;
- 10 (52) Triazolam;
- 11 (53) Zaleplon;
- 12 (54) Zolpidem; [~~and~~]
- 13 (55) Zopiclone (Lunesta) [~~-~~]; and
- 14 (56) Brexanolone."

15 SECTION 6: Section 329-20, Hawaii Revised Statutes, is
16 amended by amending subsection (d) to read as follows:

17 "(d) Stimulants. Unless listed in another schedule, any
18 material, compound, mixture, or preparation which contains any
19 quantity of the following substances having a stimulant effect
20 on the central nervous system, including its salts, isomers, and
21 salts of such isomers whenever the existence of such salts,

H.B. NO. 1032

1 isomers, and salts of isomers is possible within the specific
2 chemical designation:

3 (1) Cathine ((+)-norpseudoephedrine);

4 (2) Diethylpropion;

5 (3) Fencamfamin;

6 (4) Fenproporex;

7 (5) Mazindol;

8 (6) Mefenorex;

9 (7) Modafinil;

10 (8) Phentermine;

11 (9) Pemoline (including organometallic complexes and
12 chelates thereof);

13 (10) Pipradrol;

14 (11) Sibutramine;

15 (12) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine);

16 [~~and~~]

17 (13) Lorcaserin[+]; and

18 Solriamfetol."

19 SECTION 7. Section 329-22, Hawaii Revised Statutes, is
20 amended to read as follows:

21 "**§329-22 Schedule V.** (a) The controlled substances
22 listed in this section are included in schedule V.

H .B. NO. 1032

1 (b) Narcotic drugs containing nonnarcotic active medicinal
2 ingredients. Any compound, mixture, or preparation containing
3 limited quantities of any of the following narcotic drugs, which
4 also contains one or more nonnarcotic active medicinal
5 ingredients in sufficient proportion to confer upon the
6 compound, mixture, or preparation, valuable medicinal qualities
7 other than those possessed by the narcotic drug alone:

8 (1) Not more than 200 milligrams of codeine, or any of its
9 salts, per 100 milliliters or per 100 grams;

10 (2) Not more than 100 milligrams of dihydrocodeine, or any
11 of its salts, per 100 milliliters or per 100 grams;

12 (3) Not more than 100 milligrams of ethylmorphine, or any
13 of its salts, per 100 milliliters or per 100 grams;

14 (4) Not more than 2.5 milligrams of diphenoxylate and not
15 less than 25 micrograms of atropine sulfate per dosage
16 unit;

17 (5) Not more than 100 milligrams of opium per 100
18 milliliters or per 100 grams; and

19 (6) Not more than 0.5 milligram of difenoxin and not less
20 than 25 micrograms of atropine sulfate per dosage
21 unit.

tb .B. NO. 1032

1 (c) Stimulants. Unless specifically exempted or excluded
2 or unless listed in another schedule, any material, compound,
3 mixture, or preparation that contains any quantity of the
4 following substances having a stimulant effect on the central
5 nervous system, including its salts, isomers, and salts of
6 isomers.

7 (d) Depressants. Unless specifically exempted or excluded
8 or unless listed in another schedule, any material, compound,
9 mixture, or preparation that contains any quantity of the
10 following substances having a depressant effect on the central
11 nervous system, including its salts, isomers, and salts of
12 isomers:

13 (1) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-
14 propionamide], (Vimpat);

15 (2) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic
16 acid]; and

17 (3) Brivaracetam ((2S)-2[(4R)-2-oxo-4-propylpyrrolidin-1-
18 yl]butanamide) (Other names: BRV; UCB-34714; Briviact)
19 and its salts.

20 [~~(e) Approved cannabidiol drugs. A drug product in~~
21 ~~finished dosage formulation that has been approved by the United~~
22 ~~States Food and Drug Administration that contains cannabidiol~~

H.B. NO. 1032

1 ~~(2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-~~
2 ~~pentyl-1,3-benzenediol) derived from cannabis and no more than~~
3 ~~0.1 percent (w/w) residual tetrahydrocannabinols.]"~~

4 SECTION 8. Statutory material to be repealed is bracketed
5 and stricken. New statutory material is underscored.

6 SECTION 9. This Act shall take effect upon its approval.

7

8

INTRODUCED BY: _____



9

BY REQUEST

10

JAN 25 2021

H.B. NO. 1032

Report Title:

Uniform Controlled Substances Act

Description:

Updates the Uniform Controlled Substances Act, chapter 329, Hawaii Revised Statutes, to make it consistent with amendments in the federal controlled substances law as required by section 329-11, Hawaii Revised Statutes.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

JUSTIFICATION SHEET

DEPARTMENT: Public Safety

TITLE: A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

PURPOSE: To update chapter 329, Hawaii Revised Statutes (HRS), to make it consistent with amendments in the federal controlled substances law and an emergency state scheduling action.

MEANS: Amend sections 329-14(b), (e), and (g), 329-16(f), 329-20(b) and (d), and 329-22, HRS.

JUSTIFICATION: Section 329-11, HRS, requires that the Department of Public Safety recommend corresponding changes in Hawaii law.

Impact on the public: This bill is intended to protect the public by updating Hawaii's controlled substance schedules consistent with Federal law.

Impact on the department and other agencies: These proposed amendments would assist the Department's Narcotics Enforcement Division in clarifying regulations of the Uniform Controlled Substances Act.

GENERAL FUND: None.

OTHER FUNDS: None.

PPBS PROGRAM DESIGNATION: PSD 502.

OTHER AFFECTED AGENCIES: Department of Health Food and Drug Branch; federal, state, and county law enforcement.

EFFECTIVE DATE: Upon approval.